Accelerated corneal crosslinking concurrent with LASIK

Article

Combination thearpy may provide option for reducing keratectasia

Ectatic changes can arise as early as 1 week after LASIK, or they can be delayed, occuring several years after the initial procedure.4,5 In many cases, penetrating keratoplasty is eventually performed to manage this complication. The incidence of keratectasia after LASIK has been estimated to be 0.04% to 0.6%.6,7 However, accurate clinical studies of incidence are not available.8,9 Although a number of clinical risk factors have been reported, the mechanisms of post-LASIK keratectasia remain unclear.10

Studies of the histologic changes in post-LASIK keratectasia demonstrate variable degrees of corneal thinning in the stromal bed and the flap.11 Although disruption of Bowman layer, which is typically observed in keratoconus has not been shown in most cases of postLASIK keratectasia, other pathologic findings, such as macrostriae in the stromal bed, thinning of the stromal collagen lamellae, minimal scarring at the flapstromal bed interface, lack of inflammation, and the presence of an iron ring around the area of steepening have been reported.12,13 Keratectasia after LASIK shares similar topographic and clinical characteristics with keratoconus, a noninflammatory disease characterized by thinning of the corneal stroma, defects in the Bowman layer, and protrusion of the central cornea.14,15

Collagen crosslinking (CXL) has emerged as a promising technique to slow or stop the progression of post-LASIK ectasia.18,19 The technique of corneal crosslinking involves photopolymerization of stromal fibres by the combined action of a photosensitizing substance (riboflavin) and UV light. Photopolymerization increases the rigidity of the corneal collagen and its resistance to deformation.

The most commonly used procedure for corneal crosslinking was described by Wollensak et al.20 The UVA illumination associated with this method uses a 3 mW/cm2 irradience, 370 nm source illuminating the riboflavin treated eye for 30 minutes, a cumulative dose of 5.4 J/cm2 .

The combination of LASIK and accelerated CXL may provide a method to reduce the risk of postoperative keratectasia in a population in which at risk patients are difficult to discern. In this small sample pilot group, we assessed the applicability of the technique of accelerated CXL procedures when performed in conjunction with LASIK at the time of operation.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.